Skip to content
DataLookout
Menu

NCT06144944

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

StatusActive, Not Recruiting
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 21 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Study completion moved earlier from Dec 31, 2031 to Jan 31, 2031
    • Secondary endpoints: details revised at 2 of 10 entries
  2. Minor Primary completion date changed from estimate of Jun 30, 2026 to Jul 18, 2026v7
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v6
  4. Notable Eligibility criteria shortened, about 2 words
    • Interventions: Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel (Drug), Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel… to Epirubicin or doxorubicin, cyclophosphamide, paclitaxel (Drug), Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel (Drug)
    • Study title shortened, about 4 words
    v4
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 1, 2024 to Jan 17, 2024
    • Site details revised
    v3
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Residual Cancer Burden 0/1 rate as assessed by independent central review
Timeframe: Within 4 weeks after surgery

Secondary (10)

Residual Cancer Burden 0/1 rate as assessed by local pathology review
Pathological complete response rate
Objective response rate
Breast conservation surgery rate
Health-related Quality of Life 1
Show 5 moreShow less
Health-related Quality of Life 2
5-year event-free survival
5-year overall survival
Safety (AEs+SAEs)
Biomarkers (Immune cell subpopulations quantities)

Arms and interventions

Neoadjuvant pyrotinib combined with chemotherapyExperimental
Neoadjuvant chemotherapyPlacebo comparator

Drugs: Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel

Sites

1 site in 1 country

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityGuangzhou, Guangdong, China